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This special issue brings together a series of articles
resulting from two recent symposia which focussed on
homocysteine metabolism and related disorders.
The 7th International conference on homocysteine metab-
olism took place in Prague from the 21st to the 25th of June,
2009. This conference was the latest in the series following
those held in Dromoland Castle Co. Clare, Ireland in 1995, in
Nijmegen, the Netherlands in 1998, in Sorrento, Italy in 2001,
in Basel, Switzerland in 2003, in Milan, Italy in 2005 and in
Saarbrücken, Germany in 2007. In 2011 this meeting is
planned to take place in Lisbon, Portugal. This conference
tries to link basic science with clinical applications in the field
of homocysteine, a field which has seen a dramatic increase in
interest over the last 20 years. Current issues were addressed
in Plenary sessions on: metabolites and their trafficking;
genes; patho-physiology of disturbed C-1 and sulphur amino
acid pool; 3 free communication sessions; 2 sessions on
lessons from intervention trials and fortification.
Two articles bring to attention two relatively poorly
addressed pathways which could well be of increasing future
importance. The extensive review by Ueland (doi:10.1007/
s10545-010-9088-4) on choline and betaine emphasises the
importance of these metabolites in essential processes and
recent studies on their possible links to chronic disease. The
review by Stipanuk on the metabolic processes between
cysteine and taurine and inorganic sulphur highlights that
homocysteine can be a “good guy” in acting as precursor of
this important pathway (doi:10.1007/s10545-010-9006-9).
The key enzyme in homocysteine catabolism, cystathionine
β-synthase, is central to three articles. The paper by Magner
et al. (doi:10.1007/s10545-010-9146-y) points out a chang-
ing clinical spectrum of cystathionine synthase deficiency as
patients with a mainly vascular disease pathology are
discovered partly as a result of the recent focus on mild
hyperhomocysteinaemia as a risk factor. Current focus on
chaperone effects on this enzyme are highlighted in the
paper of Kopecka and colleagues (doi:10.1007/s10545-010-
9087-5). A new approach to the assay of cystathionine
synthase using tandem MS/MS somewhat surprisingly
shows that this enzyme is detectable in plasma with
diagnostic implications (doi:10.1007/s10545-010-9178-3).
The transport of homocysteine has received relatively little
attention and therefore the paper byGlazier et al. (doi:10.1007/
s10545-010-9141-3) is especially welcome with potential
implications for the role of homocysteine in pregnancy.
There is always great interest in epidemiological aspects
of homocysteine as a risk factor at such meetings and the
report of the large multi-centre study on the effect of
vitamin intervention on the secondary occurrence of
vascular disease was greatly anticipated. The largely
negative results are disappointing but some authors ques-
tion the extrapolation of these findings to exclude possible
benefits on primary events.
The controversial issue of cobalamin fortification of food
is addressed in the article by Carmel (doi:10.1007/s10545-
010-9150-2). This author argues against fortification,
certainly at the present time but it must be borne in mind
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that there is a counter argument within the overall context
of B vitamin fortification of foodstuffs and hopefully this
article will contribute to debate on this topic.
The annual international meeting on inborn errors of
metabolism organised in Fulda, Germany by the SHS
company brings together clinicians and basic scientists to
explore advances and their implications for treatment and
outcome in patients with rare inborn errors of metabolism.
We were very pleased that for this year it was decided to
revisit the topic “Homocysteine, Folate and Cobalamin
disorders” just 13 years after it first appeared.
The meeting was opened with an extensive review of
related pathways with reference to vascular disease and
neural tube defects reported in the article by Henk Blom
(doi:10.1007/s10545-010-9177-4).
We were fortunate that Robert Clarke repeated his
presentation from Prague here (doi:10.1007/s10545-010-
9235-y). In addressing the so called homocysteine contro-
versy Yvo Mulders (doi:10.1007/s10545-010-9151-1) rai-
ses several possible limitations on the previous intervention
studies that seem plausible and which might moderate the
mainly negative conclusions and he convincingly argues
that homocysteine is far from dead. The paper by Susan
Duthie on “Folate and cancer: how DNA damage, DNA
repair and DNA methylation impact on colon carcinogen-
esis” (doi:10.1007/s10545-010-9128-0) is a valuable and
very informative review of one example of the possible
involvement homocysteine and folate in a common disease.
The current interest in vitamin B12 and its disorders is
reflected by five related articles.
The presentation on cobalamin status in the general
childhood population reported an approach to nutritional
studies that is unfamiliar to most paediatricians in the
inborn errors field (doi:10.1007/s10545-010-9119).
Inborn errors related to cobalamin are well represented
with four papers.
One of the several transport defects, transcobalamin
deficiency is covered in the article by Nissen from the
group of Ebba Nexo which reports the complexity of
mutation analysis in this disorder (printed as abstract only,
doi:10.1007/s10545-010-9145-z).
The elegant studies leading to the discovery of the gene
for the cblF defect of intracellular metabolism which were
rather surprisingly based on homozygosity mapping in
several unrelated families are reported by Rutsch
(doi:10.1007/s10545-010-9083-9).
A comprehensive review of clinical presentation and
outcome of the Cbl C defect by Martinelli et al. emphasises
pathogenetic aspects and sets the scene for the future
studies necessary to try to improve outcome in this difficult
to treat disorder (doi:10.1007/s10545-010-9161-z).
The question of impact of treatment on the remethylation
defects is extended to other disorders by Schiff et al. calling
on the vast experience from one main centre involved in
care of such patients (doi:10.1007/s10545-010-9120-8).
Finally the paper by Rozen brings out the elegant, detailed
studies that are possible in appropriate animal models, in this
case for deficiency of the key folate enzyme, methylenete-
trahydrofolate reductase (doi:10.1007/s10545-010-9127-1).
All in all the variety of papers in the special issue
emphasise the importance of homocysteine as a key
metabolite that is linked to several basic biological
processes and therefore not surprisingly involved in these
several disease processes.
Brian Fowler
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